ICER Researcher Raises Concern Over Possible FDA Full Approval of DMD Treatment

Using Sarepta’s treatment for Duchenne muscular dystrophy (DMD) as an example, a researcher from the Institute for Clinical Review (ICER) said in a recent article that the FDA should be cautious in granting full approval to drugs that fail confirmatory tests.
Source: Drug Industry Daily